Top Markets
#1 Black Phoenix Black Phoenix +355.52%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.17%
#4 Akedo Akedo +48.78%
#5 Acurast Acurast +29.95%
#6 BasedHype BasedHype +23.54%
#7 Cryptopia Cryptopia +21.54%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +21.11%
#9 Avantis Avantis +20.16%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +15.50%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Immatics biotechnologies GmbH Immatics biotechnologies GmbH

Immatics biotechnologies GmbH

IMTXW
Kedudukan dalam Saham #40865
Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to... Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T cell-redirecting immunotherapies designed to combat cancer, primarily targeting the United States market for treatment applications. Their research and development efforts are concentrated on creating targeted immunotherapies for solid tumors, employing two distinct therapeutic strategies: adoptive cell therapies (ACTs) and antibody-like T-cell receptor (TCR) Bispecifics. Immatics N.V. boasts a robust pipeline of product candidates. Among these are IMA203, an immunotherapy targeting solid tumors, and IMA203CD8, a cell therapy product, both currently undergoing Phase 1b clinical trials. Additionally, their earlier-stage assets include IMA204, designed to target tumor stroma, and IMA30x, an allogeneic cellular therapy candidate, both of which are in preclinical development. The company is also progressing with its TCR Bispecifics portfolio, featuring IMA401 in Phase 1b clinical trials, alongside IMA402 and IMA403, which are presently in preclinical phases. Furthermore, Immatics N.V. has established strategic alliances to bolster its development efforts. These include a partnership with MD Anderson Cancer Center for the advancement of various T cell and TCR-based adoptive cellular therapies, an agreement with Celgene Corporation focused on creating innovative adoptive cell therapies for diverse cancers, and a collaboration with Genmab A/S aimed at developing T cell-engaging bispecific immunotherapies for multiple oncological indications. The company's corporate headquarters are situated in Tübingen, Germany.
Harga Saham
$0.0006
Disegerakkan terakhir: 2025-06-30
Modal Pasaran
$69.91K
Perubahan (1 hari)
-88.46%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Immatics biotechnologies GmbH (IMTXW)

Kategori

Healthcare
Nisbah P/E bagi Immatics biotechnologies GmbH (IMTXW)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Immatics biotechnologies GmbH, nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Immatics biotechnologies GmbH dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.